{"id":"par-101-opt-80","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL1255800","moleculeType":"Small molecule","molecularWeight":"1058.05"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"OPT-80 is a fidaxomicin analog, a non-absorbed macrocyclic antibiotic that selectively targets bacterial RNA polymerase in C. difficile while minimizing systemic absorption and disruption of normal gut flora. It acts locally in the gastrointestinal tract to eliminate C. difficile while preserving beneficial commensal bacteria, reducing recurrence rates compared to vancomycin.","oneSentence":"PAR-101/OPT-80 is a non-systemic antibiotic that binds to bacterial RNA polymerase to inhibit Clostridioides difficile growth in the colon.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:25:35.867Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Clostridioides difficile infection (CDI), including recurrent CDI"}]},"trialDetails":[{"nctId":"NCT02437591","phase":"PHASE4","title":"Study to Evaluate the Pharmacokinetics of Fidaxomicin in Inflammatory Bowel Disease (IBD) Subjects With Clostridium Difficile Infection (CDI)","status":"COMPLETED","sponsor":"Astellas Pharma Europe Ltd.","startDate":"2015-08-13","conditions":"Inflammatory Bowel Disease (IBD), Clostridium Difficile Infection (CDI)","enrollment":25},{"nctId":"NCT02179658","phase":"PHASE3","title":"A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD)","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2014-06-23","conditions":"Clostridium Difficile","enrollment":210},{"nctId":"NCT02254967","phase":"PHASE4","title":"A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population","status":"COMPLETED","sponsor":"Astellas Pharma Europe Ltd.","startDate":"2014-11-06","conditions":"Clostridium Difficile","enrollment":364},{"nctId":"NCT02692651","phase":"PHASE4","title":"A Comparison of Fidaxomicin and Vancomycin in Patients With CDI Receiving Antibiotics for Concurrent Infections","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2017-05-01","conditions":"Clostridium Difficile Infection (CDI)","enrollment":144},{"nctId":"NCT01591863","phase":"PHASE2","title":"Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)","status":"COMPLETED","sponsor":"Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2012-06-15","conditions":"Clostridium Difficile-associated Diarrhea","enrollment":38},{"nctId":"NCT01691248","phase":"PHASE3","title":"Safety and Efficacy of Fidaxomicin Versus Placebo for Prophylaxis Against Clostridium Difficile-Associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation (MK-5119-001)","status":"COMPLETED","sponsor":"Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2012-10-10","conditions":"Clostridium Difficile-Associated Diarrhea (CDAD)","enrollment":611},{"nctId":"NCT00468728","phase":"PHASE3","title":"PAR-101/OPT-80 Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD)","status":"COMPLETED","sponsor":"Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2006-10-04","conditions":"Clostridium Infections, Diarrhea","enrollment":535},{"nctId":"NCT00314951","phase":"PHASE3","title":"Fidaxomicin Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) (MK-5119-018)","status":"COMPLETED","sponsor":"Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2006-05-02","conditions":"Clostridium Infections, Diarrhea","enrollment":629},{"nctId":"NCT01813448","phase":"PHASE1","title":"A Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Fidaxomicin in Healthy Male Japanese and Caucasian Subjects","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2013-02","conditions":"Pharmacokinetics of Fidaxomicin, Healthy Subjects","enrollment":36}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":18,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"PAR-101/OPT-80","genericName":"PAR-101/OPT-80","companyName":"Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","companyId":"optimer-pharmaceuticals-llc-a-subsidiary-of-merck-co-inc-rahway-new-jersey-usa","modality":"Small molecule","firstApprovalDate":"","aiSummary":"PAR-101/OPT-80 is a non-systemic antibiotic that binds to bacterial RNA polymerase to inhibit Clostridioides difficile growth in the colon. Used for Clostridioides difficile infection (CDI), including recurrent CDI.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}